CCO James Wilbur to depart 10x Genomics on Feb 1, 2024; gets severance

10x Genomics, Inc.

James Wilbur, Chief Commercial Officer, leaving effective Feb 1, 2024; no disagreement with management.
Severance: six months base salary plus one-time COBRA payment of $14,335.
No 2023 annual performance bonus for Wilbur.
Departure not related to company's operations, financial statements, or policies.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Wilbur

Chief Commercial Officer

TXG · 10x Genomics, Inc.

Effective: 2024-02-01
Filed: January 16, 2024, 6:59 PM ET

On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the “Company”) entered into a Transition and Separation Agreement (the “Agreement”) pursuant to which Dr. Wilbur will depart the Company on February 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Wilbur departed as Chief Commercial Officer at 10x Genomics, Inc..

Action: departed
Role: Chief Commercial Officer

Exact text from the filing

On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the “Company”) entered into a Transition and Separation Agreement (the “Agreement”) pursuant to which Dr. Wilbur will depart the Company on February 1, 2024.

View on SEC.gov

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.